Precision medicine in Acute Respiratory Distress Syndrome
1
Issued Date
2022-09-01
Resource Type
ISSN
13345605
eISSN
1845206X
Scopus ID
2-s2.0-85137320895
Journal Title
Signa Vitae
Volume
18
Issue
5
Start Page
75
End Page
85
Rights Holder(s)
SCOPUS
Bibliographic Citation
Signa Vitae Vol.18 No.5 (2022) , 75-85
Suggested Citation
Heijnen N.F.L., Bergmans D.C.J.J., Schultz M.J., Bos L.D.J. Precision medicine in Acute Respiratory Distress Syndrome. Signa Vitae Vol.18 No.5 (2022) , 75-85. 85. doi:10.22514/sv.2021.233 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85566
Title
Precision medicine in Acute Respiratory Distress Syndrome
Other Contributor(s)
Abstract
Many patients with acute respiratory failure fulfill the diagnosis of Acute Respiratory Distress Syndrome (ARDS), forming a very heterogeneous population. Clinical trials have not yielded beneficial treatment effects in ARDS, possibly caused by this heterogeneity. Dividing patients with ARDS into subgroups, each with similar characteristics, may result in improved treatment strategies as part of a precision medicine approach. In this systematic review, we summarize the subphenotypes identified so far, the current state, and future directions for precision medicine in ARDS. Multiple data-driven subphenotypes have been identified based on a wide range of variables. These subphenotypes are associated with differences in clinical outcomes, which could be used for prognostic-and predictive enrichment of future interventional studies. True treatable traits have not been identified yet, deeper phenotyping will hopefully reveal these along with mechanistic differences.